Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2015

Open Access 01-12-2015 | Research

Enhanced humoral response in pregnant mice immunized with liposome encapsulated recombinant neutralizing epitope protein of Hepatitis- E virus

Authors: Shivali Shirish Joshi, Vidya Avinash Arankalle

Published in: Virology Journal | Issue 1/2015

Login to get access

Abstract

Background

Pregnant women from developing countries are at high-risk of hepatitis E-associated high mortality and constitute priority population for vaccination. So far, candidate vaccines have not been evaluated during pregnancy. We evaluated our vaccine candidate, recombinant Neutralizing Epitope protein (rNEp) encapsulated in liposomes, in pregnant mice.

Methods

A single dose (10 μg) of the formulation was administered intramuscularly on day 7 of pregnancy. Titres of serum IgG antibodies to hepatitis E virus (IgG-anti-HEV), levels of cytokines and biochemical parameters were determined. Spleens were harvested from pregnant and non-pregnant mice for immunophenotyping (flow cytometry), cytokines (cytometric bead array, CBA) and gene expression of immune response genes (Taqman low density array, TLDA). Histopathology studies of spleen, liver, kidneys, brain and muscle was carried out.

Results

The vaccine was well-tolerated during pregnancy as evidenced by histopathology and serum biochemical parameters. Anti-HEV titres were significantly higher in the pregnant balb/c and C57BL/6 mice (3592 ± 802 and1016 ± 138 respectively, than in non-pregnant groups (634 ± 191 and 320 ± 55 respectively, p < 0.001 for both) suggesting that the higher antibody response in pregnant mice was independent of the genetic makeup of the host but immunogen-driven. Pups receiving vertically transferred antibodies developed lower anti-HEV antibodies (p < 0.05) when immunized with the formulation after seronegativity than in the age-matched mice without such antibodies. In non-pregnant mice, a Th1 response and discordance between splenic and serum cytokines was evident while in pregnancy, a Th2 bias was observed irrespective of immunization. Increased CD19 levels correlated with higher anti-HEV titres in pregnant mice.

Conclusion

The single dose of the vaccine was safe and highly immunogenic in pregnant mice. Degree and type of immune response to vaccination during pregnancy is immunogen-driven. In-depth studies are needed to understand the underlying immunologic mechanism(s). These encouraging results for a vaccine intended for use in pregnant women should be confirmed in higher animals.
Literature
1.
Teshale EH, Hu DJ, Holmberg SD. The two faces of hepatitis E virus. Clin Infect Dis. 2010;51:328–34.CrossRefPubMed
2.
Zhou YH, Purcell RH, Emerson SU. Truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus. Vaccine. 2005;23:3157–65.CrossRefPubMed
3.
Li SW, Zhang J, Li YM, Ou SH, Huang GY, He ZQ, et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine. 2005;23:2893–901.CrossRefPubMed
4.
Kamili S, Spelbring J, Carson D, Krawczynski K. Protective efficacy of hepatitis E virus DNA vaccine administered by gene gun in the cynomolgus macaque model of infection. J Infect Dis. 2004;189:258–64.CrossRefPubMed
5.
Li TC, Suzaki Y, Ami Y, Dhole TN, Miyamura T, Takeda N. Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles. Vaccine. 2004;22:370–7.CrossRefPubMed
6.
Ma H, Song X, Harrison TJ, Li R, Huang G, Zhang H, et al. Immunogenicity and efficacy of a bacterially expressed HEV ORF3 peptide, assessed by experimental infection of primates. Arch Virol. 2009;154:1641–8.CrossRefPubMed
7.
Huang WJ, Zhang HY, Harrison TJ, Lan HY, Huang GY, Wang YC. Immunogenicity and protective efficacy in rhesus monkeys of a recombinant ORF2 protein from hepatitis E virus genotype 4. Arch Virol. 2009;154:481–8.CrossRefPubMed
8.
Arankalle VA, Lole KS, Deshmukh TM, Srivastava S, Shaligram US. Challenge studies in Rhesus monkeys immunized with candidate hepatitis E vaccines: DNA, DNA-prime-protein-boost and DNA-protein encapsulated in liposomes. Vaccine. 2009;27:1032–9.CrossRefPubMed
9.
Zhang M, Emerson SU, Nguyen H, Engle R, Govindarajan S, Blackwelder WC, et al. Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques. Vaccine. 2002;20:3285–91.CrossRefPubMed
10.
Im SW, Zhang JZ, Zhuang H, Che XY, Zhu WF, Xu GM, et al. A bacterially expressed peptide prevents experimental infection of primates by the hepatitis E virus. Vaccine. 2001;19:3726–32.CrossRefPubMed
11.
Purdy MA, McCaustland KA, Krawczynski K, Spelbring J, Reyes GR, Bradley DW. Preliminary evidence that a trpE-HEV fusion protein protects cynomolgus macaques against challenge with wild-type hepatitis E virus (HEV). J Med Virol. 1993;41:90–4.CrossRefPubMed
12.
Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376:895–902.CrossRefPubMed
13.
Shrestha MP, Scott RM, Joshi DM, Mammen Jr MP, Thapa GB, Thapa N, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med. 2007;356:895–903.CrossRefPubMed
14.
Wu T, Zhu FC, Huang SJ, Zhang XF, Wang ZZ, Zhang J, et al. Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology. 2012;55:2038.CrossRefPubMed
15.
Zhang J, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, et al. Long-term efficacy of a hepatitis E vaccine. N Engl J Med. 2015;372:914–22.CrossRefPubMed
16.
Zhou YH, Purcell RH, Emerson SU. An ELISA for putative neutralizing antibodies to Hepatitis E virus detects antibodies to genotypes 1, 2, 3 and 4. Vaccine. 2004;22:2578–85.CrossRefPubMed
17.
Li S, Tang X, Seetharaman J, Yang C, Gu Y, Zhang J, et al. Dimerization of hepatitis E virus capsid protein E2s domain is essential for virus-host interaction. PLoS Pathog. 2009;5(8), e1000537.CrossRefPubMedCentralPubMed
18.
Deshmukh TM, Lole KS, Tripathy AS, Arankalle VA. Immunogenicity of candidate hepatitis E virus DNA vaccine expressing complete and truncated ORF2 in mice. Vaccine. 2007;25:4350–60.CrossRefPubMed
19.
Shrivastava S, Lole KS, Tripathy AS, Shaligram US, Arankalle VA. Development of candidate combination vaccine for hepatitis E and hepatitis B: a liposome encapsulation approach. Vaccine. 2009;27:6582–8.CrossRefPubMed
20.
Bischoff AL, Følsgaard NV, Carson CG, Stokholm J, Pedersen L, Holmberg M, et al. Altered response to A (H1N1) pnd09 vaccination in pregnant women: a single blinded randomized controlled trial. Plos one. 2013;8(4), e56700.CrossRefPubMedCentralPubMed
21.
Sudarshan MK, Madhusudana SN, Mahendra BJ, Ashwathnarayana DH, Jayakumary M, Gangaboriah. Post exposure rabies prophylaxis with Purified Verocell Rabies Vaccine: a study of immune response in pregnant women and their matched controls. Indian J Public Health. 1999;43:76–8.PubMed
22.
Magnusson SE, Reimer JM, Karlsson KH, Lilja L, Bengtsson KL, Stertman L. Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine. 2013;31:1725–33.CrossRefPubMed
23.
Korsholm KS, Agger EM, Foged C, Christensen D, Dietrich J, Andersen CS, et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology. 2007;121:216–26.CrossRefPubMed
24.
De Becker G, Moulin V, Pajak B, Bruck C, Francotte M, Thiriart C, et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. IntImmunol. 2000;12:807–15.
25.
Hannesdottir SG, Olafsdottir TA, Giudice GD, Jonsdottir I. Adjuvants LT-K63 and CpG enhance the activation of dendritic cells in neonatal mice. Scand J Immunol. 2008;68:469–75.CrossRefPubMed
26.
Negi VD, Nagarajan AG, Chakravortty D. A safe vaccine (DV-STM-07) against Salmonella infection prevents abortion and confers protective immunity to the pregnant and new born mice. PLoS One. 2010;5(2), e9139.CrossRefPubMedCentralPubMed
27.
Song YJ, Park WJ, Lee SK, Lee JB, Park SY, Song CS, et al. Induction of antibody and interferon-γ production in mice immunized with virus-like particles of swine hepatitis E virus. J Vet Sci. 2014;15:575–8.CrossRefPubMedCentralPubMed
28.
Valensi JP, Carlson JR, Van Nest GA. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. Jimmunol. 1994;153:4029–39.
29.
Kumar M, Sudeep AB, Arankalle VA. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine. 2012;30:6142–9.CrossRefPubMed
30.
Athanassakis I, Iconomidou B. Cytokine production in the serum and spleen of mice from day 6 to 14 of gestation: cytokines/placenta/spleen/serum. Dev Immunol. 1996;4:247–55.CrossRefPubMed
31.
Orsi NM, Gopichandran N, Ekbote UV, Walker JJ. Murine serum cytokines throughout the estrous cycle, pregnancy and post partum period. Anim Reprod Sci. 2006;96:54–65.CrossRefPubMed
32.
Keene JD. Ribonucleoprotein infrastructure regulating the flow of genetic information between the genome and the proteome. Proc Natl AcadSci. 2001;98:7018–24.CrossRef
33.
Jiménez de Oya N, Alonso-Padilla J, Blázquez AB, Escribano-Romero E, Escribano JM, Saiz JC. Maternal transfer of antibodies to the offspring after mice immunization with insect larvae-derived recombinant hepatitis E virus ORF-2 proteins. Virus Res. 2011;158:28–32.CrossRefPubMed
34.
Bell BP, Negus S, Fiore AE, Plotnik J, Dhotre KB, Williams J, et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr Infect Dis J. 2007;26:116–22.CrossRefPubMed
35.
Njie-Jobe J, Nyamweya S, Miles DJ, Van Der Sande M, Zaman S, Touray E, et al. Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years. Vaccine. 2012;30:2543–50.CrossRefPubMedCentralPubMed
36.
Appaiahgari MB, Glass R, Singh S, Taneja S, Rongsen-Chandola T, Bhandari N, et al. Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. Vaccine. 2014;32:651–6.CrossRefPubMed
37.
Wang Z, Zhang S, Luo C, Wu Q, Liu Q, Zhou YH, et al. Transplacentally acquired maternal antibody against hepatitis B surface antigen in infants and its influence on the response to hepatitis B vaccine. PLoS One. 2011;6(9), e25130.CrossRefPubMedCentralPubMed
38.
Bavdekar SB, Naik S, Nadkarni SS, Kamat JR, Deshpande JM, Vaswani LK. Effect of passively transferred anti-poliovirus antibodies on seroconversion. Indian J Pediatr. 1999;66:45–8.CrossRefPubMed
39.
Johansson E, Istrate C, Charpilienne A, Cohen J, Hinkula J, Poncet D, et al. Amount of maternal rotavirus-specific antibodies influence the outcome of rotavirus vaccination of newborn mice with virus-like particles. Vaccine. 2008;26:778–85.CrossRefPubMed
40.
Saravanabalaji S, Tripathy AS, Dhoot RR, Chadha MS, Kakrani AL, Arankalle VA. Viral load, antibody titres and recombinant open reading frame 2 protein-induced Th1/Th2 cytokines and cellular immune responses in self-limiting and fulminant hepatitis E. Intervirology. 2009;52:78–85.CrossRefPubMed
41.
Patil DR, Hundekar SL, Arankalle VA. Expression profile of immune response genes during acute myopathy induced by chikungunya virus in a mouse model. Microbes Infect. 2012;14:457–69.CrossRefPubMed
Metadata
Title
Enhanced humoral response in pregnant mice immunized with liposome encapsulated recombinant neutralizing epitope protein of Hepatitis- E virus
Authors
Shivali Shirish Joshi
Vidya Avinash Arankalle
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2015
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-015-0302-8

Other articles of this Issue 1/2015

Virology Journal 1/2015 Go to the issue

Research

The multifunctional protein CI of potyviruses plays interlinked and distinct roles in viral genome replication and intercellular movement

Research

Hepatitis B serologic survey and review of immunization records of children, adolescents and adults in Fiji, 2008–2009

Research

Lung ultrasonography for the diagnosis of 11 patients with acute respiratory distress syndrome due to bird flu H7N9 infection

Review

Dried blood spots PCR assays to screen congenital cytomegalovirus infection: a meta-analysis

Research

Establishment and application of cross-priming isothermal amplification coupled with lateral flow dipstick (CPA-LFD) for rapid and specific detection of red-spotted grouper nervous necrosis virus

Research

A model with combined viral and metabolic factors effectively predicts HBeAg status under long term entecavir therapy: a prospective cohort study

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits